Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib with Platinum-based Chemotherapy in Recurrent Ovarian Cancer
NCT03056833Phase 1Completed
- Start
- Jun 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC). Primary endpoint: Maximal Tolerated Dose at 56 days. Started Jun 2017; status: completed.
02
Drugs
ribociclib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03056833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056833.